Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Feasibility of Placing Bravo PH Capsule in Proximal Esophagus (bravo)
This study is currently recruiting participants.
Verified by Vanderbilt University, August 2008
Sponsored by: Vanderbilt University
Information provided by: Vanderbilt University
ClinicalTrials.gov Identifier: NCT00378898
  Purpose

Assessing the feasibility and patient tolerance to placement of Bravo PH capsule in proximal esophagus.

There will be no difference in patient-perception of a proximally-placed Bravo esophageal pH monitor compared with a distal monitor.


Condition Intervention Phase
Gastroesophageal Reflux Disease
Device: Bravo PH capsule
Procedure: Fluoroscopy
Phase III

MedlinePlus related topics: GERD X-Rays
Drug Information available for: X-Rays
U.S. FDA Resources
Study Type: Interventional
Study Design: Diagnostic, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety Study
Official Title: DUAL BRAVO PH MONITORING: A Feasibility Trial

Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • Patient tolerance to a Bravo PH monitor in the proximal esophagus after 48 hours [ Time Frame: 48 hours ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Collection of and comparison of data between distal and proximal Bravo capsule [ Time Frame: 48 hours ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 25
Study Start Date: September 2006
Estimated Study Completion Date: January 2009
Estimated Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: Bravo PH capsule
    standard of care egd with bravo placement
    Procedure: Fluoroscopy
    one time "xray" to determine evacuation of bravo
Detailed Description:

24-hour pH monitoring is often considered the "gold standard" in the diagnosis of GERD and is increasingly utilized in patients with extra-esophageal symptoms (1). However, the clinical utility of pH monitoring in this patient population remains controversial. An important limitation of traditional pH catheters is their suboptimal sensitivity especially in patients with extraesophageal GERD. Vaezi et al. tested reproducibility and reliability of the proximal and distal esophageal pH probe in 32 patients (2). Among these patients,11 were controls, 10 had distal reflux, and 11 had both proximal and distal reflux. In this group of patients the sensitivity of distal and proximal pH probes were 70% and 55%, respectively. Additionally, a more recent study by Shaker et al. showed the number and duration of hypopharyngeal reflux events to be similar between the control subjects and patients with reflux laryngitis and vasomotor rhinitis (3).

Poor sensitivity of catheter based pH monitoring in detecting acid reflux may be due to day to day variability of test, its less than adequate reliability as well as possible intermittent nature of the reflux events (not recorded in only a 24-hour period) (4). Additionally, since the traditional ambulatory device is commonly placed transnasally through the oropharynx into the esophagus, patients often complain of throat and nose discomfort and usually restrict their daily activity. This potentially leads to false negative findings and reduced test sensitivity. Furthermore, incorrect results may be collected if the pH electrode slips away from the initial manometrically determined placement site. In light of these limitations, a new wireless (catheter free) pH monitoring device was developed to improve patient comfort and increase test sensitivity. The Bravo pH monitoring system (Medtronic Inc, Minneapolis, MN) uses a radiotelemetric capsule temporarily attached to the esophageal mucosa which transmits pH data to a receiver carried on patient's belt.

Although well studied in the distal esophagus, there are currently no studies in adults assessing the feasibility and patient tolerance to placement of this device more proximally. Such a placement may increase the sensitivity of the test and add to our ability to study potential predictors of treatment response in patients with extraesophageal GERD.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Inclusion criteria will include the following:
  • Patients greater than or equal to 18 years of age
  • Patients having regularly scheduled upper endoscopy with planned Bravo pH monitor testing
  • Patients with known GERD based on symptoms (heartburn, regurgitation) and response to a proton pump inhibitor or esophagitis on EGD as well as those with extraesophageal GERD (cough, asthma and throat discomfort).

Exclusion Criteria:

  • Exclusion criteria will include the following:
  • Previous surgical procedures to the upper esophagus
  • History of bleeding diathesis or coagulopathy
  • Stroke or transient ischemic attack within the past 6 months
  • GI bleeding within the previous 6 months
  • Known esophageal varices
  • Significant medical illness (i.e., congestive heart failure)
  • Pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00378898

Contacts
Contact: barbara mccafferty, rn 615-322-1897 barbara.mccafferty@vanderbilt.edu
Contact: tonya givens, RN 615-936 1745 tonya.givens@vanderbilt.edu

Locations
United States, Tennessee
Vanderbilt University Medical Center, Vanderbilt Digestive Disease Clinic, TVC, Room 1660 Recruiting
Nashville, Tennessee, United States, 37232-5280
Contact: barbara mccafferty, rn     615-322-1897     barbara.mccafferty@vanderbilt.edu    
Principal Investigator: Michael Vaezi, MD            
The Vanderbilt Clinic/ Endoscopy Lab Recruiting
Nashville, Tennessee, United States, 37232-5280
Contact: barbara mccafferty, rn     615-322-1897     barbara.mccafferty@vanderbilt.edu    
Contact: tonya givens, rn     615 936-1745     tonya.givens@vanderbilt.edu    
Principal Investigator: Michael F Vaezi, MD. PHD            
Sponsors and Collaborators
Vanderbilt University
Investigators
Principal Investigator: Michael F Vaezi, MD PhD MS Vanderbilt University
  More Information

Responsible Party: vanderbilt university medical center ( michael f. vaezi, md, phd, ms, epi )
Study ID Numbers: 060724
Study First Received: September 20, 2006
Last Updated: August 8, 2008
ClinicalTrials.gov Identifier: NCT00378898  
Health Authority: United States: Institutional Review Board;   United States: Food and Drug Administration;   United States: Federal Government

Study placed in the following topic categories:
Deglutition Disorders
Esophageal Motility Disorders
Digestive System Diseases
Esophageal disorder
Gastrointestinal Diseases
Esophageal Diseases
Gastroesophageal Reflux

ClinicalTrials.gov processed this record on January 14, 2009